A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelbine is an important chemotherapy option for MBC. W...

Full description

Saved in:
Bibliographic Details
Main Authors: Janni, Wolfgang, Sarosiek, Tomasz, Karaszewska, Boguslawa, Pikiel, Joanna, Staroslawska, Elzbieta, Potemski, Piotr, Salat, Christoph, Brain, Etienne, Caglevic, Christian, Briggs, Kathryn, DeSilvio, Michelle, Marini, Luca, Papadimitriou, Christos
Format: Artigo
Language:Inglês
Published: Springer US 2014
Subjects:
Clinical Trial
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3907671/
https://ncbi.nlm.nih.gov/pubmed/24402830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2828-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items